|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
SU14813
|
MedKoo Code#: 202710
|
|
Name:
SU14813
|
|
CAS#:
627908-92-3
Synonym:
SU14813;
1H-Pyrrole-3-carboxamide,
5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl-
;
IUPAC/Chemical name:
(S,Z)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-N-(2-hydroxy-3-morpholinopropyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide
|
|
Chemical structure: |
Theoretical analysis
|
|
|
Chemical Formula: C23H27FN4O4
Exact Mass: 442.20163
Molecular Weight: 442.48
m/z: 442.20163 (100.0%), 443.20499 (24.9%),
444.20834 (3.0%), 443.19867 (1.5%)
Elemental Analysis: C, 62.43; H, 6.15;
F, 4.29; N, 12.66; O, 14.46
|
|
Availability and price:
This agent is not in stock, which may be available through custom synthesis. To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Quality control
data:
Product will be shipped with
supporting analytical data.
|
|
Information about this agent
|
SU14813, a small molecule identified from
the same chemical library used to isolate sunitinib, has
broad-spectrum RTK inhibitory activity through binding to and
inhibition of VEGFR, PDGFR, KIT, and FLT3. In cellular assays,
SU14813 inhibited ligand-dependent and ligand-independent
proliferation, migration, and survival of endothelial cells
and/or tumor cells expressing these targets. SU14813
inhibited VEGFR-2, PDGFR-ß, and FLT3 phosphorylation in
xenograft tumors in a dose- and time-dependent fashion. ([Mol
Cancer Ther 2006;5(7):1774–82).
Current developer:
Pfizer Inc。
1: Lee ES, Rewolinski D. Evaluation of CXCR4
inhibition in the prevention and intervention model of laser-induced
choroidal neovascularization. Invest Ophthalmol Vis Sci. 2009 Dec 30. [Epub
ahead of print] PubMed PMID: 20042641.
2: Wang L, Wang J, Blaser BW, Duchemin AM, Kusewitt DF, Liu T, Caligiuri
MA, Briesewitz R. Pharmacologic inhibition of CDK4/6: mechanistic
evidence for selective activity or acquired resistance in acute myeloid
leukemia. Blood. 2007 Sep 15;110(6):2075-83. Epub 2007 May 30. PubMed
PMID: 17537993.
3: Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H,
Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO,
Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D. SU14813: a novel
multiple receptor tyrosine kinase inhibitor with potent antiangiogenic
and antitumor activity. Mol Cancer Ther. 2006 Jul;5(7):1774-82. PubMed
PMID: 16891463.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
